357 related articles for article (PubMed ID: 36765782)
1. MicroRNAs with Multiple Targets of Immune Checkpoints, as a Potential Sensitizer for Immune Checkpoint Inhibitors in Breast Cancer Treatment.
Zhou H; Jia W; Lu L; Han R
Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765782
[TBL] [Abstract][Full Text] [Related]
2. The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle.
Masoumi E; Tahaghoghi-Hajghorbani S; Jafarzadeh L; Sanaei MJ; Pourbagheri-Sigaroodi A; Bashash D
J Control Release; 2021 Dec; 340():168-187. PubMed ID: 34743998
[TBL] [Abstract][Full Text] [Related]
3. Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors.
Dutta S; Ganguly A; Chatterjee K; Spada S; Mukherjee S
Biology (Basel); 2023 Jan; 12(2):. PubMed ID: 36829496
[TBL] [Abstract][Full Text] [Related]
4. Enhancing HCC Treatment: innovatively combining HDAC2 inhibitor with PD-1/PD-L1 inhibition.
Han R; Ling C; Wang Y; Lu L
Cancer Cell Int; 2023 Sep; 23(1):203. PubMed ID: 37716965
[TBL] [Abstract][Full Text] [Related]
5. The Risks of miRNA Therapeutics: In a Drug Target Perspective.
Zhang S; Cheng Z; Wang Y; Han T
Drug Des Devel Ther; 2021; 15():721-733. PubMed ID: 33654378
[TBL] [Abstract][Full Text] [Related]
6. Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia.
Al Nuhait M; Bajnaid E; Al Otaibi A; Al Shammari A; Al Awlah Y
Sci Prog; 2021; 104(1):36850421997302. PubMed ID: 33689534
[No Abstract] [Full Text] [Related]
7. Key questions about the checkpoint blockade-are microRNAs an answer?
Dragomir M; Chen B; Fu X; Calin GA
Cancer Biol Med; 2018 May; 15(2):103-115. PubMed ID: 29951335
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects.
Makaremi S; Asadzadeh Z; Hemmat N; Baghbanzadeh A; Sgambato A; Ghorbaninezhad F; Safarpour H; Argentiero A; Brunetti O; Bernardini R; Silvestris N; Baradaran B
Biomedicines; 2021 Aug; 9(9):. PubMed ID: 34572263
[TBL] [Abstract][Full Text] [Related]
9. Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4.
Pandey P; Khan F; Qari HA; Upadhyay TK; Alkhateeb AF; Oves M
Pharmaceuticals (Basel); 2022 Mar; 15(3):. PubMed ID: 35337133
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
Yang J; Chen J; Wei J; Liu X; Cho WC
Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
[TBL] [Abstract][Full Text] [Related]
11. CAXII inhibitors: Potential sensitizers for immune checkpoint inhibitors in HCC treatment.
Han R; Li J; Hony J; Xiao Z; Wang J; Yao M; Liang S; Lu L
Front Immunol; 2023; 14():1052657. PubMed ID: 37006233
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitors for triple-negative breast cancer: From immunological mechanisms to clinical evidence.
Farshbafnadi M; Pastaki Khoshbin A; Rezaei N
Int Immunopharmacol; 2021 Sep; 98():107876. PubMed ID: 34146865
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitors: The Emerging Cornerstone in Cholangiocarcinoma Therapy?
Gutiérrez-Larrañaga M; González-López E; Roa-Bautista A; Rodrigues PM; Díaz-González Á; Banales JM; López-Hoyos M; Santos-Laso A; Crespo J
Liver Cancer; 2021 Nov; 10(6):545-560. PubMed ID: 34950178
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitors: review of the existing evidence and challenges in breast cancer.
Jalalvand M; Darbeheshti F; Rezaei N
Immunotherapy; 2021 May; 13(7):587-603. PubMed ID: 33775102
[TBL] [Abstract][Full Text] [Related]
15. Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies.
Chyuan IT; Chu CL; Hsu PN
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33801815
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management.
Wang H; Mustafa A; Liu S; Liu J; Lv D; Yang H; Zou J
Front Pharmacol; 2019; 10():1254. PubMed ID: 31708780
[TBL] [Abstract][Full Text] [Related]
17. Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired.
Marei HE; Hasan A; Pozzoli G; Cenciarelli C
Cancer Cell Int; 2023 Apr; 23(1):64. PubMed ID: 37038154
[TBL] [Abstract][Full Text] [Related]
18. Current state and future of co-inhibitory immune checkpoints for the treatment of glioblastoma.
Shen S; Chen L; Liu J; Yang L; Zhang M; Wang L; Zhang R; Uemura Y; Wu Q; Yu X; Liu T
Cancer Biol Med; 2020 Aug; 17(3):555-568. PubMed ID: 32944390
[TBL] [Abstract][Full Text] [Related]
19. An overview of immune checkpoint therapy in autoimmune diseases.
Mohammadi P; Hesari M; Chalabi M; Salari F; Khademi F
Int Immunopharmacol; 2022 Jun; 107():108647. PubMed ID: 35228033
[TBL] [Abstract][Full Text] [Related]
20. A genomic instability-related lncRNA model for predicting prognosis and immune checkpoint inhibitor efficacy in breast cancer.
Jiao Y; Li S; Wang X; Yi M; Wei H; Rong S; Zheng K; Zhang L
Front Immunol; 2022; 13():929846. PubMed ID: 35990656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
